Malaria Pathogenesis and Human Immunity

$1,428,771ZIAFY2017AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 28494763 Paper 28469130 Paper 28454546 Paper 28378857 Paper 28289193 Paper 28158202 Paper 27994033 Paper 27993160 Paper 27838188 Paper 27825353 Paper 27818095 Paper 27798646 Paper 27784313 Paper 27776514 Paper 27660233 Paper 27655345 Paper 27577697 Paper 27348299 Paper 27337450 Paper 27296389 Paper 27182597 Paper 26774243 Paper 26742574 Paper 26701602 Paper 26687956 Paper 26485448 Paper 26390866 Paper 26373337 Paper 26283745 Paper 26237549 Paper 26137505 Paper 26130295 Paper 25954766 Paper 25928499 Paper 25851174 Paper 25712365 Paper 25599401 Paper 25590756 Paper 25502314 Paper 25183768 Paper 25156731 Paper 25075834 Paper 25049249 Paper 24948693 Paper 24923250 Paper 24867977 Paper 24867976 Paper 24849722 Paper 24688070 Paper 24675047 Paper 24647281 Paper 24515897 Paper 24352242 Paper 24338354 Paper 24246501 Paper 24225303 Paper 24124591 Paper 24042109 Paper 24035558 Paper 23939897 Paper 23733143 Paper 23696730 Paper 23624527 Paper 23612201 Paper 23562882 Paper 23555917 Paper 23542146 Paper 23448727 Paper 23349902 Paper 23347631 Paper 23144611 Paper 23071567 Paper 22992802 Paper 22855752 Paper 22722859 Paper 22634344 Paper 22623996 Paper 22459624 Paper 22445352 Paper 22393475 Paper 22321373 Paper 22270182 Paper 21998476 Paper 21992120 Paper 21823261 Paper 21786288 Paper 21673999 Paper 21532754 Paper 20529864 Paper 20493844 Paper 20101240 Paper 19729847 Paper 19503809 Paper 19325374 Paper 18752444 Paper 18192399 Paper 18005721 Paper 17355169 Paper 17283083 Paper 17156402

Abstract

Our program's multidisciplinary research activities are carried out at several NIH-sponsored laboratories and clinics in malaria-endemic regions of Mali and Cambodia, where we investigate four subject areas: (1) the molecular mechanism by which sickle-cell trait (hemoglobin S) confers protection to Plasmodium falciparum malaria; (2) the parasite and host factors that influence the rate of P. falciparum parasite clearance in patients treated with the antimalarial drug artemisinin; (3) the molecular mechanisms of P. falciparum resistance to frontline antimalarial drugs, including artemisinin and piperaquine; and (4) the role of Anopheles mosquito vectors in the spread of multidrug-resistant P. falciparum parasites. In each of these areas we seek research advances that improve our knowledge of disease processes and drug-resistance mechanisms in patients with malaria, with the ultimate goal of developing new antimalarial therapeutics, vaccines, and transmission-blocking interventions to prevent infection, illness, and death.

View original record on NIH RePORTER →